Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|5|1471-1478

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.5, 2015-05, pp. : 1471-1478

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir‐containing regimens without sofosbuvir

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 126-133

John Wiley & Sons Inc

Access to resources Recommend Favorite

O‐28: Safety and efficacy of ledipasvir/sofosbuvir for the treatment of hepatitis c infection: interim analysis of a prospective, observational study

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 17-17

John Wiley & Sons Inc

Access to resources Recommend Favorite